- βDirectly adapted from a US teaching kitchen model, making findings highly applicable to American diabetes care programs
- βUses continuous glucose monitoring to capture real-world blood sugar variability, going beyond simple HbA1c snapshots
- βCombines cooking skills with sleep, mindfulness, and physical activity β addressing the full lifestyle picture of diabetes management
| Country | Japan |
| Journal | BMJ open |
| Year | 2025 |
| Authors | Baden, Kawamoto, Kagisaki |
| PMID | 40854839 |
A study from Japan is putting a uniquely practical tool at the center of diabetes care: the kitchen. Researchers at the University of Osaka have launched the Teaching Kitchen for Diabetes in Japan (TKD-J) trial, a rigorous randomized controlled trial testing whether hands-on culinary education β combined with lessons on nutrition, movement, sleep, and mindfulness β can meaningfully improve blood sugar control in people with type 2 diabetes.
What the Study Involves
The trial will enroll 200 Japanese adults between the ages of 20 and 79, all living with type 2 diabetes and carrying HbA1c levels between 6.5% and 8.9% β a range that spans from the diagnostic threshold to moderately uncontrolled diabetes. Participants must also have a BMI of 23 kg/mΒ² or higher, or meet abdominal obesity criteria (waist circumference of 33.5 inches or more for men, or 35.4 inches or more for women).
Half of the participants will begin the program immediately, while the other half will serve as a control group for four months before starting. The full program runs 12 months: four months of weekly sessions followed by eight months of monthly check-ins. A final four-month follow-up period rounds out the 16-month study window.
The primary goal is straightforward: does HbA1c drop during that first four-month intensive phase? Secondary measures include fasting blood glucose (converted from mmol/L targets: a healthy fasting glucose goal in US terms is under 130 mg/dL per ADA guidelines), glucose variability tracked through continuous glucose monitoring, weight, diet quality, physical activity, sleep, cooking confidence, and quality of life.
Rooted in a US Model
What makes this Japanese study especially relevant for American patients is its origin story. The TKD-J trial is explicitly modeled on the US Teaching Kitchen Multisite Trial, adapting that American framework for Japanese dietary culture and healthcare norms. In other words, Japan is taking a concept born in the United States, refining it, and testing it rigorously β and the results flowing back across the Pacific could strengthen the evidence base for teaching kitchen programs here at home.
The US program emphasized that food literacy β knowing how to prepare healthy meals β is a missing link in chronic disease management. Japan's adaptation adds a personalized approach and web-based tracking, modernizing the model for today's patients.
Why This Matters for US Patients
The American Diabetes Association recommends medical nutrition therapy and diabetes self-management education as cornerstones of type 2 diabetes care β yet access to hands-on, practical food education remains limited for most Americans. Teaching kitchen programs exist at institutions like Harvard and the Cleveland Clinic, but they are far from standard care.
This Japanese trial, published in BMJ Open (2025), provides a new, high-quality data point. If the TKD-J trial confirms that structured cooking education improves HbA1c, reduces glucose variability, and builds lasting behavioral skills, it will add international weight to advocacy efforts pushing for broader insurance coverage and hospital integration of these programs in the US.
For patients managing type 2 diabetes today, the message is clear: what happens in your kitchen may be as important as what happens in your doctor's office. Ask your care team whether a diabetes-focused cooking or nutrition education program is available in your area.
Source: Baden, Kawamoto, Kagisaki. "Efficacy of a teaching kitchen program for patients with type 2 diabetes in Japan: protocol for an open-label randomised controlled trial (TKD-J trial)." BMJ Open, 2025. DOI: 10.1136/bmjopen-2025-105580. PMID: 40854839.
